The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 378
- Parkinson's+Pathway+Biomarkers
Filter Results (2440)
- LEAPS, 2005Michael J. Fox Foundation Validation Study
The role of genetics in PD continues to be a major focus in the field and much of what we know about possible underlying mechanisms of PD cause and pathogenesis has come through studies of genes (e.g...
- Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2005Mechanisms of Graft-Induced Dyskinesias in an Animal Model of Parkinson's Disease (Supplemental Funding)
Our ongoing project has four aims:
- To develop a model of graft-induced dyskinesia (GID) in the rat, which will provide a cost-effective tool for studying the mechanisms of this complication;
- To...
- The Role of Inflammation in Parkinson's Disease, 2005Development of a Dominant-Negative TNF Lentiviral Approach
Because TNF inhibitors are not believed to cross the blood-brain barrier, an orally administered TNF-based therapy is not currently possible. The Foundation has awarded supplemental funding to drive...
- Community Fast Track, 2005Nigrostriatal Dopaminergic Degeneration and Alpha-synuclein Aggregation in Mice with Reduced TrkB Signaling
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons and deposition of cytoplasmic protein aggregates termed Lewy bodies (LB) in a brain structure termed substantia...
- Community Fast Track, 2005Pathophysiological Role of PINK1 in Rodent Brain
Mutations in the PINK1 gene were recently linked to autosomal recessive parkinsonism. However, to date, very little is known about the role of PINK1 in the brain. Our group has ample expertise with...
- Community Fast Track, 2005Novel Therapeutic Approaches for Parkinson ’s Disease
Our goal is to develop novel therapeutic agents for the treatment of Parkinson's disease. We will focus on two compounds. One of these blocks the mitochondrial permeability transition (MPT), which is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.